Articles: sars-cov-2.
-
Limited evidence is available on the real-world effectiveness of the BNT162b2 vaccine against coronavirus disease 2019 (Covid-19) and specifically against infection with the omicron variant among children 5 to 11 years of age. ⋯ Our findings suggest that as omicron was becoming the dominant variant, two doses of the BNT162b2 messenger RNA vaccine provided moderate protection against documented SARS-CoV-2 infection and symptomatic Covid-19 in children 5 to 11 years of age. (Funded by the European Union through the VERDI project and others.).
-
This cross-sectional study examines monthly blood donations from individuals aged 16 years and older to estimate the population with antibodies to SARS-CoV-2 from infection or vaccination.